<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044859</url>
  </required_header>
  <id_info>
    <org_study_id>ADP-0055-001</org_study_id>
    <nct_id>NCT04044859</nct_id>
  </id_info>
  <brief_title>Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors</brief_title>
  <official_title>A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adaptimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adaptimmune</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in
      subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and
      whose synovial sarcoma, myxoid/round cell liposarcoma (MRCLS), melanoma, urothelial, head and
      neck, ovarian, gastric (stomach), esophagogastric junction (EGJ), non-small cell lung
      (NSCLC), or esophageal cancer that express the MAGE-A4 protein.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2018</start_date>
  <completion_date type="Anticipated">January 14, 2036</completion_date>
  <primary_completion_date type="Anticipated">January 14, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with treatment -related adverse events (AEs), including serious adverse events (SAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</measure>
    <time_frame>2.5 years</time_frame>
    <description>Determine if treatment with ADP-A2M4CD8 is safe and tolerable through assessment of adverse events (AEs) including Serious Adverse Events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate safety of ADP-A2M4CD8 through measurement of Replication -competent Retrovirus in genetically engineered T-cells</measure>
    <time_frame>15 years</time_frame>
    <description>Evaluation of RCL using PCR -based assay in peripheral blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumour activity: Overall Response Rate (ORR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>ORR is defined as incidence of complete responses or partial responses as assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity: Best overall response (BOR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>BOR is per RECIST V1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>For patients who are observed to respond to ADP-A2M4CD8, the time taken from date of infusion to achieve a partial response or complete response (TTR) is assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>For patients who are observed to respond to ADP-A2M4CD8, the DOR is the date of initial response (including confirmation) from date of infusion up until disease progression per RECIST v 1.1 or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stable disease (DoSD)</measure>
    <time_frame>2.5 years</time_frame>
    <description>For patients who are observed to have stable disease by RECIST v 1.1, the duration of period of stable disease until disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>2.5 years</time_frame>
    <description>PFS is assessed from date of infusion of ADP-A2M4CD8 up until the date of disease progression per RECIST v1.1 or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>15 years</time_frame>
    <description>OS is assessed from date of infusion of ADP-A2M4CD8 up until the date of patient death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Synovial Sarcoma</condition>
  <condition>Myxoid/Round Cell Liposarcoma (MRCLS)</condition>
  <condition>Melanoma</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Head and Neck</condition>
  <condition>Ovarian</condition>
  <condition>Gastric Cancer</condition>
  <condition>Esophagogastric Junction Disorder</condition>
  <condition>Nonsmall Cell Lung Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Autologous genetically modified ADP-A2M4CD8 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Autologous genetically modified ADP-A2M4CD8 cells</intervention_name>
    <description>Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1</description>
    <arm_group_label>Autologous genetically modified ADP-A2M4CD8 cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Key Inclusion criteria

          -  Age ≥18 and ≤ 75 years

          -  Subject is positive for at least 1 HLA-A*02 inclusion allele

          -  Histologically or cytogenetically confirmed diagnosis of urothelial cancer, melanoma,
             ovarian cancer, esophageal , esophagogastric junction (EGJ) cancer, gastric cancer,
             non-small cell lung carcinoma (NSCLC), head and neck, synovial sarcoma or myxoid/round
             cell liposarcoma (MRCLS)

          -  Measurable disease according to RECIST v1.1 prior to leukapheresis and
             lymphodepletionHLA-A*02 positive.

          -  Tumor shows MAGE-A4 expression as confirmed by central laboratory

          -  ECOG Performance Status of 0 or 1.

          -  Left ventricular ejection fraction (LVEF) ≥50% or the institutional lower limit of
             normal range, whichever is lower Note: other protocol defined Inclusion/Exclusion
             criteria may apply

        Key exclusion criteria

          -  Positive for any HLA-A*02 allele other than: one of the inclusion alleles

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to fludarabine, cyclophosphamide or other agents used in the study

          -  Active autoimmune or immune mediated disease

          -  Leptomeningeal disease, carcinomatous meningitis or symptomatic CNS metastases

          -  Other prior malignancy that is not considered by the Investigator to be in complete
             remission. Clinically significant cardiovascular disease

          -  Uncontrolled intercurrent illness

          -  Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C
             virus, or human T cell leukemia virus

          -  Pregnant or breastfeeding

        Note: other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Hong, MD</last_name>
    <phone>713-563-5844</phone>
    <email>dshong@madanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Panzini</last_name>
      <phone>617-724-4377</phone>
      <email>cpanzini@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Donald Lawrence, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University - School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nic Perry</last_name>
      <phone>314-362-6470</phone>
      <email>nperry@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Tanner M Johanns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Cameron</last_name>
      <phone>716-845-1780</phone>
      <email>Heather.Cameron@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Adekunle O Odunsi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center, Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna Savage</last_name>
      <phone>916-668-1462</phone>
      <email>shawna.savage@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey M Clarke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Lowery</last_name>
      <phone>405-271-8777</phone>
      <email>Cynthia-Lowery@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Asch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Scott</last_name>
      <email>Allison.Scott@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Carabasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Racquel Ingram</last_name>
      <phone>844-482-4812</phone>
      <email>racquel.ingram@sarahcannon.com</email>
    </contact>
    <contact_backup>
      <last_name>Chris Earwood</last_name>
      <email>Chris.Earwood@sarahcannon.com</email>
    </contact_backup>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danxia Ke</last_name>
      <phone>713-792-4384</phone>
      <email>DKe@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>David Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaylee Meisinger</last_name>
      <email>kmeisinger@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>John A Charlson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genevieve Mendiola</last_name>
      <phone>416-634-7940</phone>
      <email>genevieve.mendiola@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Marcus Butler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 De Octubre</name>
      <address>
        <city>Madrid</city>
        <state>Avenida De Cordoba S/n</state>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Gutierrez</last_name>
      <email>unidadfase1.imas12@h12o.es</email>
    </contact>
    <investigator>
      <last_name>Jose Lopez-Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Start Madrid-FJD, Fundación Jimѐnez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Armellini</last_name>
      <email>adriana.armellini@startmadrid.com</email>
    </contact>
    <investigator>
      <last_name>Victor Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico, Clara Campal, HM CIOCC (START MADRID-CIOCC)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalmazio Danini</last_name>
      <phone>620423957</phone>
      <email>dalmazio.danini@startmadrid.com</email>
    </contact>
    <investigator>
      <last_name>Emiliano Calvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell Therapy</keyword>
  <keyword>T Cell Therapy</keyword>
  <keyword>SPEAR T Cell</keyword>
  <keyword>MAGE-A4</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Synovial Sarcoma</keyword>
  <keyword>Myxoid/Round Cell Liposarcoma (MRCLS)</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Urothelial</keyword>
  <keyword>Head and Neck</keyword>
  <keyword>Ovarian</keyword>
  <keyword>Gastric (stomach)</keyword>
  <keyword>Esophagogastric Junction (EGJ)</keyword>
  <keyword>Non-small Cell Lung (NSCLC)</keyword>
  <keyword>Esophageal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Liposarcoma, Myxoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

